[Cyclophosphamide--an effective immunomodulator in treating inflammatory rheumatism and severe collagenoses].
After 30 years since the synthesis of cyclophosphamide and 25 years since its first clinical utilization (V.Ciobanu), authors offer an actualized review of the data of pharmacokinetics, pharmacodynamics, pathopharmacology and clinical therapeutics, which make of cyclophosphamide an efficacious, manageable and safe drug in the treatment of the aggressive forms of collagenoses or inflammatory rheumatism. The criteria of therapeutic indication and clinical surveillance are mentioned.
Clinica Medicală, Spitalul Griviţa, Bucureşti.
V
V
Ciobanu
D I
DI
Urseanu
D000276:Adjuvants, Immunologic / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D003095:Collagen Diseases / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D012216:Rheumatic Diseases / Q000188:drug therapy*
D000276:Adjuvants, Immunologic; D003520:Cyclophosphamide
Ciclofosfamida--imunomodulator eficace în tratamentul reumatismelor inflamatorii şi colagenozelor severe.